{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:06:20Z","timestamp":1790892380535,"version":"4.1.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Hypertension"],"published-print":{"date-parts":[[1999,1]]},"abstract":"<jats:p><jats:italic>Abstract<\/jats:italic>\u2014The mechanisms for the vascular actions of vasodilatory \u03b2-blockers remain undetermined. For some kinds of \u03b2-blockers, the involvement of nitric oxide (NO) has been suggested. We studied the effects of vasodilatory \u03b2-blockers on renal perfusion pressure (RPP) and NO release in the rat kidney. Infusion of bopindolol, celiprolol, and nebivolol caused a dose-dependent reduction in RPP and an increase in NO release (RPP: bopindolol 10<jats:sup>\u22126<\/jats:sup>mol\/L, \u221223\u00b12%; celiprolol 10<jats:sup>\u22124<\/jats:sup>mol\/L, \u221227\u00b12%; nebivolol 10<jats:sup>\u22125<\/jats:sup>mol\/L, \u221235\u00b13%; NO: bopindolol 10<jats:sup>\u22126<\/jats:sup>mol\/L, +33\u00b12; celiprolol 10<jats:sup>\u22124<\/jats:sup>mol\/L, +41\u00b12; nebivolol 10<jats:sup>\u22125<\/jats:sup>mol\/L, +45\u00b15 fmol \u00b7 min<jats:sup>\u22121<\/jats:sup>\u00b7 g kidney<jats:sup>\u22121<\/jats:sup>, mean\u00b1SEM). Metergoline (10<jats:sup>\u22126<\/jats:sup>mol\/L), a 5-hydroxytryptamine (5-HT)<jats:sub>1\/2<\/jats:sub>antagonist, or NAN-190 (10<jats:sup>\u22126<\/jats:sup>mol\/L), a 5-HT<jats:sub>1A<\/jats:sub>antagonist, almost completely abolished the vasorelaxation and NO release caused by bopindolol, celiprolol, and nebivolol. However, neither propranolol nor bisoprolol decreased RPP. Celiprolol and nebivolol caused vasodilation in the rat thoracic aorta, and it was markedly reduced by endothelial denudation, N<jats:sup>\u03c9<\/jats:sup>-nitro-<jats:sc>l<\/jats:sc>-arginine methyl ester (10<jats:sup>\u22124<\/jats:sup>mol\/L), or NAN-190 (10<jats:sup>\u22126<\/jats:sup>mol\/L). In deoxycorticosterone acetate-salt hypertensive rats, 4-week administration of celiprolol (50 mg \u00b7 kg<jats:sup>\u22121<\/jats:sup>\u00b7 d<jats:sup>\u22121<\/jats:sup>IV) restored the responses regarding RPP and NO release to acetylcholine. These results suggest that several \u03b2-blockers exert their vasodilatory action through the 5-HT<jats:sub>1A<\/jats:sub>receptor\/NO pathway and that treatment with these \u03b2-blockers may protect against endothelial injury in hypertension.<\/jats:p>","DOI":"10.1161\/01.hyp.33.1.467","type":"journal-article","created":{"date-parts":[[2012,6,12]],"date-time":"2012-06-12T00:53:46Z","timestamp":1339462426000},"page":"467-471","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":69,"title":["Effects of Vasodilatory \u03b2-Adrenoceptor Antagonists on Endothelium-Derived Nitric Oxide Release in Rat Kidney"],"prefix":"10.1161","volume":"33","author":[{"given":"Masao","family":"Kakoki","sequence":"first","affiliation":[{"name":"From the Second Department of Internal Medicine, Faculty of Medicine (M.K., Y.H., H.H., H.N., Y.S., D.N., E.S., M.O.), and Faculty of Pharmaceutical Sciences (K.K., T.N.), University of Tokyo (Japan)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunobu","family":"Hirata","sequence":"additional","affiliation":[{"name":"From the Second Department of Internal Medicine, Faculty of Medicine (M.K., Y.H., H.H., H.N., Y.S., D.N., E.S., M.O.), and Faculty of Pharmaceutical Sciences (K.K., T.N.), University of Tokyo (Japan)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Hayakawa","sequence":"additional","affiliation":[{"name":"From the Second Department of Internal Medicine, Faculty of Medicine (M.K., Y.H., H.H., H.N., Y.S., D.N., E.S., M.O.), and Faculty of Pharmaceutical Sciences (K.K., T.N.), University of Tokyo (Japan)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Nishimatsu","sequence":"additional","affiliation":[{"name":"From the Second Department of Internal Medicine, Faculty of Medicine (M.K., Y.H., H.H., H.N., Y.S., D.N., E.S., M.O.), and Faculty of Pharmaceutical Sciences (K.K., T.N.), University of Tokyo (Japan)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuko","family":"Suzuki","sequence":"additional","affiliation":[{"name":"From the Second Department of Internal Medicine, Faculty of Medicine (M.K., Y.H., H.H., H.N., Y.S., D.N., E.S., M.O.), and Faculty of Pharmaceutical Sciences (K.K., T.N.), University of Tokyo (Japan)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Nagata","sequence":"additional","affiliation":[{"name":"From the Second Department of Internal Medicine, Faculty of Medicine (M.K., Y.H., H.H., H.N., Y.S., D.N., E.S., M.O.), and Faculty of Pharmaceutical Sciences (K.K., T.N.), University of Tokyo (Japan)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etsu","family":"Suzuki","sequence":"additional","affiliation":[{"name":"From the Second Department of Internal Medicine, Faculty of Medicine (M.K., Y.H., H.H., H.N., Y.S., D.N., E.S., M.O.), and Faculty of Pharmaceutical Sciences (K.K., T.N.), University of Tokyo (Japan)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Kikuchi","sequence":"additional","affiliation":[{"name":"From the Second Department of Internal Medicine, Faculty of Medicine (M.K., Y.H., H.H., H.N., Y.S., D.N., E.S., M.O.), and Faculty of Pharmaceutical Sciences (K.K., T.N.), University of Tokyo (Japan)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Nagano","sequence":"additional","affiliation":[{"name":"From the Second Department of Internal Medicine, Faculty of Medicine (M.K., Y.H., H.H., H.N., Y.S., D.N., E.S., M.O.), and Faculty of Pharmaceutical Sciences (K.K., T.N.), University of Tokyo (Japan)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Omata","sequence":"additional","affiliation":[{"name":"From the Second Department of Internal Medicine, Faculty of Medicine (M.K., Y.H., H.H., H.N., Y.S., D.N., E.S., M.O.), and Faculty of Pharmaceutical Sciences (K.K., T.N.), University of Tokyo (Japan)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_1_2","first-page":"S1","volume":"19","year":"1992","unstructured":"Prichard BN. \u03b2-blocking agents with vasodilating action. J Cardiovasc Pharmacol. 1992;19:S1\u2013S4.","journal-title":"J Cardiovasc Pharmacol"},{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00167566"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(89)91069-2"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1995.tb16339.x"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.89.4.7908610"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199605233342101"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/2.11.219S"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199106000-00016"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1159\/000176004"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/S0022-3565(25)10549-1","volume":"274","year":"1995","unstructured":"Cockcroft JR, Chowienczyk PJ, Brett SE, Chen CP, Dupont AG, Van Nueten L, Wooding SJ, Ritter JM. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine\/NO-dependent mechanism. J Pharmacol Exp Ther. 1995;274:1067\u20131071.","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/S0022-3565(25)13405-8","volume":"247","year":"1988","unstructured":"Janczewski P, Boulanger C, Iqbal A, Vanhoutte PM. Endothelium-dependent effects of carteolol. J Pharmacol Exp Ther. 1988;247:590\u2013595.","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.91.4.1229"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)49432-5"},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0022-3565(25)24496-2","volume":"272","year":"1995","unstructured":"Saeki T, Adachi H, Takase Y, Yoshitake S, Souda S, Saito I. A selective type V phosphodiesterase inhibitor, E4021, dilates porcine large coronary artery. J Pharmacol Exp Ther. 1995;272:825\u2013831.","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-198501000-00023"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.95.1.90"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.95.6.1568"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1994.tb14839.x"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.92.9.2627"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","unstructured":"Lamping KG. Response of native and stimulated collateral vessels to serotonin. Am J Physiol. 1997;272:H2409\u2013H2415.","DOI":"10.1152\/ajpheart.1997.272.5.H2409"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199001001-00004"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/335358a0"},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0026-895X(25)09017-0","volume":"41","year":"1992","unstructured":"Guan XM, Peroutka SJ, Kobilka BK. Identification of a single amino acid residue responsible for the binding of a class of \u03b2-adrenergic receptor antagonists to 5-hydroxytryptamine1A receptors. Mol Pharmacol. 1992;41:695\u2013698.","journal-title":"Mol Pharmacol"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1996.tb16015.x"}],"container-title":["Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/01.HYP.33.1.467","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T21:44:32Z","timestamp":1743371072000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/01.HYP.33.1.467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1999,1]]}},"alternative-id":["10.1161\/01.HYP.33.1.467"],"URL":"https:\/\/doi.org\/10.1161\/01.hyp.33.1.467","relation":{},"ISSN":["0194-911X","1524-4563"],"issn-type":[{"value":"0194-911X","type":"print"},{"value":"1524-4563","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,1]]},"assertion":[{"value":"1998-09-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"1998-10-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"1999-01-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}